New xenotransplantation technology raises $100m

eGenesis race to deliver safe xenotransplantation, is this a welcome reset for xeno technology?

The transplantation of animal organs to humans is still a relatively new field, that has faced significant challenges. Pig organs have long been viewed as the most compatible donor for human beings. However, retroviruses (PERVs) and our own immune systems rejecting the new organ have always stood in the way. Yet, that might soon change as a new genetic therapy from eGenesis promises to make them safe for transplantation.

The gene editing technology company eGenesis [1], announced it has raised $100 million in a series B funding round, led by venture capital firm Fresenius Medical Care, one of the world’s leading companies in end stage and chronic kidney disease treatment. Their new funding also attracted backing from Wellington Partners and Bayer’s breakthrough investment fund: Leaps.

As part of the financing, Al Wiegman, Head of Ventures at FMCV, as well as Jürgen Eckhardt and Dr Lucio Iannone, Director of Venture of Investments at Leaps by Bayer, will join the eGenesis Board of Directors. The proceeds of the funding will go towards advancing its xenotransplantation into clinical testing and support its other programs in organs such as livers, hearts and lungs from other animals.

The TRL score for this Longevity.Technology domain is currently set at: ‘Early proof of concept demonstrated in the laboratory.

TRL score 3 orange

The TRL score for the technology addressed in this article is: Early proof of concept demonstrated in the laboratory.

“The concept of cross-species organ replacement, known as xenotransplantation, has re-emerged due to recent advancements in gene editing led by eGenesis,” states eGenesis President and CEO Paul Sekhri. “…and it will become a safe and effective solution for the hundreds of thousands of patients currently on the organ transplant wait list globally.”

The potential of any technology which can deliver safe transplant of animal organs is enormous. We recently covered a breakthrough by a much smaller xeno company XenoTherapeutics which is gearing-up for its series A in 2020.

According to NHS statistics, 6178 people are waiting for organ transplant in the UK. In the US, the figure is 113,000 [2]. Approximately 400 people died in the UK last year waiting for a transplant [3].

Biotech companies are in a race to profit from xenotransplantation as the technology makes the leap from the realms of academic theory to a very probable business opportunity. The company eGenesis believes genetic technologies such as CRISPR will hold the key to moving xenotransplantation further, as it relies on the bacteria CRISPR-Cas9 which can identify and snip certain pieces DNA.

This new technology could be turned against retroviruses found in pig organs, as well as the body’s own defence system which will reject anything it perceives to foreign material. The goal is transformative. As eGenesis states on its website, they are working towards is a world in which there is no shortage of organs for transplant. In other words, they aim to solve one of the most serious issues facing Longevity.

The race is well and truly on to be the first company to deliver safe transplantation, but the road ahead may be very bumpy. Ethical and moral considerations still stand in the way. It may be difficult to obtain relevant permissions from patients.

Regulation is also lagging in some territories [4], such work used to be regulated in the UK by the UK Xenotransplantation Interim Regulatory Authority (UKXIRA). However, that was disbanded in 2006 as activity in the area slowed down. Regulatory responsibility now lies with the Human Tissue Authority, a non-departmental body of the Department of Health.

The World Health Organisation, is also concerned and has warned against the prospect of xenotourism in which people travel from the UK to countries with more relaxed rules [5]. Although there is still a long way to go, many of these obstacles also existed when human transplantation first emerged. This shows that with the growth of this technology and the advancement of xenotransplantation these issues may also be overcome. Despite it still being far from hitting the market, the interest from the healthcare sector and biotech investors is high.


[1] https://www.egenesisbio.com/egenesis-announces-100-million-series-b-financing/
[2] https://bit.ly/2qc3B57
[3] https://www.organdonor.gov/statistics-stories/statistics.html
[4] https://bit.ly/32KfFIa
[5] https://bit.ly/2X8hvS2

Phil Newman
Editor-in-Chief Phil has over 25 years of C-level management, marketing and business development expertise in Europe and North America. His creative background has helped him shape unconventional strategies for commercial growth - garnering both awards and investor ROI.

Phil has wide experience of technology transfer and the commercialisation of innovations from both private and institutional sources and this led to his interest in Longevity and the founding of Longevity.Technology.

Latest articles

VC enters Longevity market with K4Connect deal

We talk with VC investor Forte Ventures about its first foray into AgeTech, COVID-19 and the Longevity investment opportunity. Longevity agetech company K4Connect has announced...

Challenging the one drug/one disease model

A new paper supports the targeting of aging processes, rather than just one disease, to improve Longevity outcomes. Multimorbidity is a challenge for Longevity; defined...

Robotics and AI combine for new therapeutics discovery

Insilico Medicine and Arctoris announce robotics/AI partnership to focus on COVID-19 inhibitors that could have wide-reaching benefits for Longevity. Two companies have joined forces in...

The results are in: sharing our Longevity investment survey

There is rapidly-increasing activity in both the research and the investment communities that focus on Longevity; this survey gets into the details. The global Longevity...